Hypoparathyroidism: Drug Development Pipeline Study, H1 2018
The most comprehensive pipeline review “Hypoparathyroidism- Drug Development Pipeline Study” provides in-depth analysis and update information on Hypoparathyroidism pipeline drugs. Current status of all the drugs in the Hypoparathyroidism pipeline is provided in the research work.
The report provides detailed analysis of Hypoparathyroidism pipeline including companies involved, drugs in different stages of development, drug development details across regions (Region (North America, Europe, Asia Pacific and Rest of the World). Further, the Hypoparathyroidism report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Hypoparathyroidism industry.
Excerpts from- “Hypoparathyroidism- Drug Development Pipeline Study”:
Hypoparathyroidism pipeline comprises of 6 drugs under development as of February 2018. Of these, 3 drugs are in Phase 1 and 1 drug is in phase 2. Further, 2 drugs remain in Pre-clinical stage. One drug has been discontinued.
7 companies/ institutions are developing the pipeline for Dravet Sysndrome. Of this, Chugai Pharmaceuticals is developing most drugs. On the other hand, recombinant human Parathyroid Hormone (rhPTH [1-84]/ Natpar) of Shire Plc has been approved during H1 2017.
2 drugs have been assigned with orphan drug designation.
Hypoparathyroidism is relatively rare form of thyroid disorders, expected to affect around 70,000 people in the US and 260,000 people in the EU. The disease is caused when parathyroid glands fails to produce PTH (parathyroid hormone). It leads to abnormal calcium levels in the body and is not treated by hormone replacement.
The primary cause of failure of the parathyroid glands is often removal of parathyroid glands by surgery. Though rarely, family history, congenital diseases or auto-immune diseases can cause failure of the glands. Around78% of the instances is caused by surgery while 7% occurs due to family history and idiopathic (6%).
The disease is classified into two categories based on the cause of occurrence-
Key symptoms observed in Hypoparathyroidism glands include weakness, muscle cramps, numbness (paresthesias), memory loss, impaired judgment, headaches, cramps and seizures.
Scope:
The report provides detailed analysis of Hypoparathyroidism pipeline including companies involved, drugs in different stages of development, drug development details across regions (Region (North America, Europe, Asia Pacific and Rest of the World). Further, the Hypoparathyroidism report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Hypoparathyroidism industry.
Excerpts from- “Hypoparathyroidism- Drug Development Pipeline Study”:
Hypoparathyroidism pipeline comprises of 6 drugs under development as of February 2018. Of these, 3 drugs are in Phase 1 and 1 drug is in phase 2. Further, 2 drugs remain in Pre-clinical stage. One drug has been discontinued.
7 companies/ institutions are developing the pipeline for Dravet Sysndrome. Of this, Chugai Pharmaceuticals is developing most drugs. On the other hand, recombinant human Parathyroid Hormone (rhPTH [1-84]/ Natpar) of Shire Plc has been approved during H1 2017.
2 drugs have been assigned with orphan drug designation.
Hypoparathyroidism is relatively rare form of thyroid disorders, expected to affect around 70,000 people in the US and 260,000 people in the EU. The disease is caused when parathyroid glands fails to produce PTH (parathyroid hormone). It leads to abnormal calcium levels in the body and is not treated by hormone replacement.
The primary cause of failure of the parathyroid glands is often removal of parathyroid glands by surgery. Though rarely, family history, congenital diseases or auto-immune diseases can cause failure of the glands. Around78% of the instances is caused by surgery while 7% occurs due to family history and idiopathic (6%).
The disease is classified into two categories based on the cause of occurrence-
- Iatrogenic Hypoparathyroidism- arising from known causes such as surgery
- Idiopathic Hypoparathyroidism- unknown causes
- Congenital (during birth)
- Inheritance (family history)
- Auto-immune (due to auto-antibodies)
- Genetic
Key symptoms observed in Hypoparathyroidism glands include weakness, muscle cramps, numbness (paresthesias), memory loss, impaired judgment, headaches, cramps and seizures.
Scope:
- - All latest industry developments and their impact on projects and companies
- - Complete overview of global Hypoparathyroidism therapy options and treatments
- - The pipeline study reviews drug details for Hypoparathyroidism by developing companies, institutions, mechanism of action, Target, Route, Phase (pre-clinical/ Discovery, Phase 1, Phase 2, Phase 3, Pre-Registration, IND/ NDA), molecule
- - Mergers, Acquisitions, licensing, co-development and project acquisition news for Hypoparathyroidism market
- - Hypoparathyroidism drugs being developed in combination with other drugs are also detailed
- - Company wise drugs listed
1 TABLE OF CONTENTS
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 DISEASE OVERVIEW
2.2 PIPELINE SNAPSHOT
2.3 PIPELINE DRUGS BY PHASE
2.4 PIPELINE DRUGS BY COMPANY
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION
3 HYPOPARATHYROIDISM- COMPANY WISE PIPELINE ANALYSIS
3.1 ASCENDIS PHARMA A/S PIPELINE, H1 2018
3.2 CHUGAI PHARMACEUTICAL CO LTD PIPELINE, H1 2018
3.3 ELI LILLY AND CO PIPELINE, H1 2018
3.4 ENTERA BIO LTD PIPELINE, H1 2018
3.5 PHARIS BIOTEC GMBH PIPELINE, H1 2018
4 HYPOPARATHYROIDISM DRUG SNAPSHOTS
4.1 TRANSCON- PTH DRUG DETAILS
4.1.1 Snapshot
4.1.2 Drug Overview
4.1.3 Mechanism of Action
4.1.4 Current Status
4.1.5 Pre-Clinical Phase
4.2 PCO- 371 DRUG DETAILS
4.2.1 Snapshot
4.2.2 Drug Overview
4.2.3 Mechanism of Action
4.2.4 Current Status
4.2.5 Pre-Clinical Phase
4.3 SP-PTH DRUG DETAILS
4.3.1 Snapshot
4.3.2 Drug Overview
4.3.3 Mechanism of Action
4.3.4 Current Status
4.3.5 Pre-Clinical Phase
4.4 PTH-RM DRUG DETAILS
4.4.1 Snapshot
4.4.2 Drug Overview
4.4.3 Mechanism of Action
4.4.4 Current Status
4.4.5 Preclinical Phase
4.5 PTH-1-34 - ENTERA BIO DRUG DETAILS
4.5.1 Snapshot
4.5.2 Drug Overview
4.5.3 Mechanism of Action
4.5.4 Current Status
4.5.5 Phase 2 Details
4.5.6 Phase 1 Details
4.6 HEMOPARATIDE (hPTH 1-37)
4.6.1 Snapshot
4.6.2 Drug Overview
4.6.3 Mechanism of Action
4.6.4 Current Status
4.6.5 Phase 1 details
4.7 Natpar
5 RECENT DEVELOPMENTS IN HYPOPARATHYROIDISM PIPELINE
5.1 rhPTH[1-84] ADMINISTRATION TO RESULT IN BONE IMPROVEMENTS- SEPTEMBER 2017
5.2 ASCENDIS PHARMA A/S ANNOUNCES ITS TRANSCON PHASE 3 PROGRAM ON TRACK- APRIL 2017
5.3 SHIRE PLC GETS EU CONDITIONAL MARKETING AUTHORISATION FOR NATPAR FOR CHRONIC HYPOPARATHYROIDISM- APRIL 2017
6 APPENDIX
6.1 ABOUT VPA RESEARCH
6.2 SOURCES AND RESEARCH METHODOLOGY
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 DISEASE OVERVIEW
2.2 PIPELINE SNAPSHOT
2.3 PIPELINE DRUGS BY PHASE
2.4 PIPELINE DRUGS BY COMPANY
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION
3 HYPOPARATHYROIDISM- COMPANY WISE PIPELINE ANALYSIS
3.1 ASCENDIS PHARMA A/S PIPELINE, H1 2018
3.2 CHUGAI PHARMACEUTICAL CO LTD PIPELINE, H1 2018
3.3 ELI LILLY AND CO PIPELINE, H1 2018
3.4 ENTERA BIO LTD PIPELINE, H1 2018
3.5 PHARIS BIOTEC GMBH PIPELINE, H1 2018
4 HYPOPARATHYROIDISM DRUG SNAPSHOTS
4.1 TRANSCON- PTH DRUG DETAILS
4.1.1 Snapshot
4.1.2 Drug Overview
4.1.3 Mechanism of Action
4.1.4 Current Status
4.1.5 Pre-Clinical Phase
4.2 PCO- 371 DRUG DETAILS
4.2.1 Snapshot
4.2.2 Drug Overview
4.2.3 Mechanism of Action
4.2.4 Current Status
4.2.5 Pre-Clinical Phase
4.3 SP-PTH DRUG DETAILS
4.3.1 Snapshot
4.3.2 Drug Overview
4.3.3 Mechanism of Action
4.3.4 Current Status
4.3.5 Pre-Clinical Phase
4.4 PTH-RM DRUG DETAILS
4.4.1 Snapshot
4.4.2 Drug Overview
4.4.3 Mechanism of Action
4.4.4 Current Status
4.4.5 Preclinical Phase
4.5 PTH-1-34 - ENTERA BIO DRUG DETAILS
4.5.1 Snapshot
4.5.2 Drug Overview
4.5.3 Mechanism of Action
4.5.4 Current Status
4.5.5 Phase 2 Details
4.5.6 Phase 1 Details
4.6 HEMOPARATIDE (hPTH 1-37)
4.6.1 Snapshot
4.6.2 Drug Overview
4.6.3 Mechanism of Action
4.6.4 Current Status
4.6.5 Phase 1 details
4.7 Natpar
5 RECENT DEVELOPMENTS IN HYPOPARATHYROIDISM PIPELINE
5.1 rhPTH[1-84] ADMINISTRATION TO RESULT IN BONE IMPROVEMENTS- SEPTEMBER 2017
5.2 ASCENDIS PHARMA A/S ANNOUNCES ITS TRANSCON PHASE 3 PROGRAM ON TRACK- APRIL 2017
5.3 SHIRE PLC GETS EU CONDITIONAL MARKETING AUTHORISATION FOR NATPAR FOR CHRONIC HYPOPARATHYROIDISM- APRIL 2017
6 APPENDIX
6.1 ABOUT VPA RESEARCH
6.2 SOURCES AND RESEARCH METHODOLOGY
LIST OF FIGURES
Figure 1: Hypoparathyroidism Pipeline by Phase, H1- 2018
Figure 2: Hypoparathyroidism Pipeline by Companies, H1- 2018
Figure 3: Company wise Pipeline Drug Phases, H1- 2018
Figure 4: Hypoparathyroidism Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018
Figure 1: Hypoparathyroidism Pipeline by Phase, H1- 2018
Figure 2: Hypoparathyroidism Pipeline by Companies, H1- 2018
Figure 3: Company wise Pipeline Drug Phases, H1- 2018
Figure 4: Hypoparathyroidism Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Hypoparathyroidism Pipeline by Phase, H1- 2018
Table 2: Hypoparathyroidism Pipeline by Companies, H1- 2018
Table 3: Hypoparathyroidism Pipeline by Mechanism of Action, H1- 2018
Table 4: Ascendis Pharma A/S - Hypoparathyroidism Pipeline, H1- 2018
Table 5: Chugai Pharmaceutical Co Ltd - Hypoparathyroidism Pipeline, H1- 2018
Table 6: Eli Lilly and Co - Hypoparathyroidism Pipeline, H1- 2018
Table 7: Entera Bio Ltd - Hypoparathyroidism Pipeline, H1- 2018
Table 8: Pharis Biotec GmbH - Hypoparathyroidism Pipeline, H1- 2018
Table 1: Hypoparathyroidism Pipeline by Phase, H1- 2018
Table 2: Hypoparathyroidism Pipeline by Companies, H1- 2018
Table 3: Hypoparathyroidism Pipeline by Mechanism of Action, H1- 2018
Table 4: Ascendis Pharma A/S - Hypoparathyroidism Pipeline, H1- 2018
Table 5: Chugai Pharmaceutical Co Ltd - Hypoparathyroidism Pipeline, H1- 2018
Table 6: Eli Lilly and Co - Hypoparathyroidism Pipeline, H1- 2018
Table 7: Entera Bio Ltd - Hypoparathyroidism Pipeline, H1- 2018
Table 8: Pharis Biotec GmbH - Hypoparathyroidism Pipeline, H1- 2018
